Treatment outcome of localized prostate cancer by 70 gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon

Hyunjung Kim, Jun Won Kim, Sung Joon Hong, Koon Ho Rha, Chang Geol Lee, Seung Choul Yang, Young Deuk Choi, Chang Ok Suh, Jaeho Cho

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: We aimed to analyze the treatment outcome and long-term toxicity of 70 Gy hypofractionated intensity-modulated radiotherapy (IMRT) for localized prostate cancer using a customized rectal balloon. Materials and Methods: We reviewed medical records of 86 prostate cancer patients who received curative radiotherapy between January 2004 and December 2011 at our institution. Patients were designated as low (12.8%), intermediate (20.9%), or high risk (66.3%). Thirty patients received a total dose of 70 Gy in 28 fractions over 5 weeks via IMRT (the Hypo-IMRT group); 56 received 70.2 Gy in 39 fractions over 7 weeks via 3-dimensional conformal radiotherapy (the CF-3DRT group, which served as a reference for comparison). A customized rectal balloon was placed in Hypo-IMRT group throughout the entire radiotherapy course. Androgen deprivation therapy was administered to 47 patients (Hypo-IMRT group, 17; CF-3DRT group, 30). Late genitourinary (GU) and gastrointestinal (GI) toxicity were evaluated according to the Radiation Therapy Oncology Group criteria. Results: The median follow-up period was 74.4 months (range, 18.8 to 125.9 months). The 5-year actuarial biochemical relapse-free survival rates for low-, intermediate-, and high-risk patients were 100%, 100%, and 88.5%, respectively, for the Hypo-IMRT group and 80%, 77.8%, and 63.6%, respectively, for the CF-3DRT group (p < 0.046). No patient presented with acute or late GU toxicity ≥grade 3. Late grade 3 GI toxicity occurred in 2 patients (3.6%) in the CF-3DRT group and 1 patient (3.3%) in the Hypo-IMRT group. Conclusion: Hypo-IMRT with a customized rectal balloon resulted in excellent biochemical control rates with minimal toxicity in localized prostate cancer patients.

Original languageEnglish
Pages (from-to)187-197
Number of pages11
JournalRadiation Oncology Journal
Volume32
Issue number3
DOIs
Publication statusPublished - 2014 Sep 1

Fingerprint

Intensity-Modulated Radiotherapy
Prostatic Neoplasms
Radiotherapy
Conformal Radiotherapy
Radiation Oncology
Androgens
Medical Records
Survival Rate
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{62bd7f6cd3674f8a8ded764a89337184,
title = "Treatment outcome of localized prostate cancer by 70 gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon",
abstract = "Purpose: We aimed to analyze the treatment outcome and long-term toxicity of 70 Gy hypofractionated intensity-modulated radiotherapy (IMRT) for localized prostate cancer using a customized rectal balloon. Materials and Methods: We reviewed medical records of 86 prostate cancer patients who received curative radiotherapy between January 2004 and December 2011 at our institution. Patients were designated as low (12.8{\%}), intermediate (20.9{\%}), or high risk (66.3{\%}). Thirty patients received a total dose of 70 Gy in 28 fractions over 5 weeks via IMRT (the Hypo-IMRT group); 56 received 70.2 Gy in 39 fractions over 7 weeks via 3-dimensional conformal radiotherapy (the CF-3DRT group, which served as a reference for comparison). A customized rectal balloon was placed in Hypo-IMRT group throughout the entire radiotherapy course. Androgen deprivation therapy was administered to 47 patients (Hypo-IMRT group, 17; CF-3DRT group, 30). Late genitourinary (GU) and gastrointestinal (GI) toxicity were evaluated according to the Radiation Therapy Oncology Group criteria. Results: The median follow-up period was 74.4 months (range, 18.8 to 125.9 months). The 5-year actuarial biochemical relapse-free survival rates for low-, intermediate-, and high-risk patients were 100{\%}, 100{\%}, and 88.5{\%}, respectively, for the Hypo-IMRT group and 80{\%}, 77.8{\%}, and 63.6{\%}, respectively, for the CF-3DRT group (p < 0.046). No patient presented with acute or late GU toxicity ≥grade 3. Late grade 3 GI toxicity occurred in 2 patients (3.6{\%}) in the CF-3DRT group and 1 patient (3.3{\%}) in the Hypo-IMRT group. Conclusion: Hypo-IMRT with a customized rectal balloon resulted in excellent biochemical control rates with minimal toxicity in localized prostate cancer patients.",
author = "Hyunjung Kim and Kim, {Jun Won} and Hong, {Sung Joon} and Rha, {Koon Ho} and Lee, {Chang Geol} and Yang, {Seung Choul} and Choi, {Young Deuk} and Suh, {Chang Ok} and Jaeho Cho",
year = "2014",
month = "9",
day = "1",
doi = "10.3857/roj.2014.32.3.187",
language = "English",
volume = "32",
pages = "187--197",
journal = "Radiation Oncology Journal",
issn = "2234-1900",
publisher = "Korean Society for Therapeutic Radiology and Oncology",
number = "3",

}

Treatment outcome of localized prostate cancer by 70 gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon. / Kim, Hyunjung; Kim, Jun Won; Hong, Sung Joon; Rha, Koon Ho; Lee, Chang Geol; Yang, Seung Choul; Choi, Young Deuk; Suh, Chang Ok; Cho, Jaeho.

In: Radiation Oncology Journal, Vol. 32, No. 3, 01.09.2014, p. 187-197.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment outcome of localized prostate cancer by 70 gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon

AU - Kim, Hyunjung

AU - Kim, Jun Won

AU - Hong, Sung Joon

AU - Rha, Koon Ho

AU - Lee, Chang Geol

AU - Yang, Seung Choul

AU - Choi, Young Deuk

AU - Suh, Chang Ok

AU - Cho, Jaeho

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Purpose: We aimed to analyze the treatment outcome and long-term toxicity of 70 Gy hypofractionated intensity-modulated radiotherapy (IMRT) for localized prostate cancer using a customized rectal balloon. Materials and Methods: We reviewed medical records of 86 prostate cancer patients who received curative radiotherapy between January 2004 and December 2011 at our institution. Patients were designated as low (12.8%), intermediate (20.9%), or high risk (66.3%). Thirty patients received a total dose of 70 Gy in 28 fractions over 5 weeks via IMRT (the Hypo-IMRT group); 56 received 70.2 Gy in 39 fractions over 7 weeks via 3-dimensional conformal radiotherapy (the CF-3DRT group, which served as a reference for comparison). A customized rectal balloon was placed in Hypo-IMRT group throughout the entire radiotherapy course. Androgen deprivation therapy was administered to 47 patients (Hypo-IMRT group, 17; CF-3DRT group, 30). Late genitourinary (GU) and gastrointestinal (GI) toxicity were evaluated according to the Radiation Therapy Oncology Group criteria. Results: The median follow-up period was 74.4 months (range, 18.8 to 125.9 months). The 5-year actuarial biochemical relapse-free survival rates for low-, intermediate-, and high-risk patients were 100%, 100%, and 88.5%, respectively, for the Hypo-IMRT group and 80%, 77.8%, and 63.6%, respectively, for the CF-3DRT group (p < 0.046). No patient presented with acute or late GU toxicity ≥grade 3. Late grade 3 GI toxicity occurred in 2 patients (3.6%) in the CF-3DRT group and 1 patient (3.3%) in the Hypo-IMRT group. Conclusion: Hypo-IMRT with a customized rectal balloon resulted in excellent biochemical control rates with minimal toxicity in localized prostate cancer patients.

AB - Purpose: We aimed to analyze the treatment outcome and long-term toxicity of 70 Gy hypofractionated intensity-modulated radiotherapy (IMRT) for localized prostate cancer using a customized rectal balloon. Materials and Methods: We reviewed medical records of 86 prostate cancer patients who received curative radiotherapy between January 2004 and December 2011 at our institution. Patients were designated as low (12.8%), intermediate (20.9%), or high risk (66.3%). Thirty patients received a total dose of 70 Gy in 28 fractions over 5 weeks via IMRT (the Hypo-IMRT group); 56 received 70.2 Gy in 39 fractions over 7 weeks via 3-dimensional conformal radiotherapy (the CF-3DRT group, which served as a reference for comparison). A customized rectal balloon was placed in Hypo-IMRT group throughout the entire radiotherapy course. Androgen deprivation therapy was administered to 47 patients (Hypo-IMRT group, 17; CF-3DRT group, 30). Late genitourinary (GU) and gastrointestinal (GI) toxicity were evaluated according to the Radiation Therapy Oncology Group criteria. Results: The median follow-up period was 74.4 months (range, 18.8 to 125.9 months). The 5-year actuarial biochemical relapse-free survival rates for low-, intermediate-, and high-risk patients were 100%, 100%, and 88.5%, respectively, for the Hypo-IMRT group and 80%, 77.8%, and 63.6%, respectively, for the CF-3DRT group (p < 0.046). No patient presented with acute or late GU toxicity ≥grade 3. Late grade 3 GI toxicity occurred in 2 patients (3.6%) in the CF-3DRT group and 1 patient (3.3%) in the Hypo-IMRT group. Conclusion: Hypo-IMRT with a customized rectal balloon resulted in excellent biochemical control rates with minimal toxicity in localized prostate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84923331952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923331952&partnerID=8YFLogxK

U2 - 10.3857/roj.2014.32.3.187

DO - 10.3857/roj.2014.32.3.187

M3 - Article

AN - SCOPUS:84923331952

VL - 32

SP - 187

EP - 197

JO - Radiation Oncology Journal

JF - Radiation Oncology Journal

SN - 2234-1900

IS - 3

ER -